Results 71 to 80 of about 4,657 (129)

Cost-effectiveness of lecanemab for early Alzheimer's disease in China. [PDF]

Alzheimers Dement
Zhao X, Xu M, Chen H, Lei Z, Yu Q, Liu J, Liao W.   +6 more
europepmc   +1 more source

Baseline CSF tau and short-term clinical change during lecanemab therapy: A prospective real-world cohort study in Japan. [PDF]

Alzheimers Dement (Amst)
Takahashi R, Kashibayashi T, Fujita J, Yoshida K, Hashiramoto A, Kowa H, Mizuta E.   +6 more
europepmc   +1 more source

Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review. [PDF]

J Clin Med
Kalampokini S, Keramidiotis I, Frontistis A, Zuchi F, Michmizos D, Papaliagkas V, Koutsouraki E.   +6 more
europepmc   +1 more source

Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181. [PDF]

J Prev Alzheimers Dis
Noguchi-Shinohara M, Muramatsu D, Shima A, Sakashita Y, Tada Y, Yamaguchi H, Komatsu J, Ikeda T, Ono K.   +8 more
europepmc   +1 more source

Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab. [PDF]

Neurol Int
Demir ÜF, Karakuş Dilbaz F.
europepmc   +1 more source

Efficacy and Safety of Recently Approved Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Meta-Analysis

International Journal of Medical Students
Background Alzheimer's disease (AD) is the leading cause of dementia worldwide and affects over 55 million people.  Lecanemab and donanemab are anti-amyloid monoclonal antibodies that flag the abnormal amyloid-beta plaques for removal by the ...
Hassan Khalid, Mohammed Murtada
doaj  

Regional amyloid-PET clearance dynamics and anti-Aβ monoclonal antibody therapy: a preliminary real-world study. [PDF]

Alzheimers Dement (Amst)
Ghirelli A, Cecchetti G, Spinelli EG, Samanes Gajate AM, Rugarli G, Pisano S, Zamboni IAL, Canu E, Castelnovo V, Sibilla E, Gilioli A, Tripodi C, Freri F, Panzacchi A, Pepe G, Chiti A, Filippi M, Agosta F.   +17 more
europepmc   +1 more source

Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France. [PDF]

J Prev Alzheimers Dis
Le Scouarnec L, Bouteloup V, Grasset L, Planche V, Chêne G, Dufouil C, MEMENTO Study Group.   +6 more
europepmc   +1 more source

Real-world clinical, biomarker, and imaging outcomes of lecanemab in Alzheimer's disease: a multicenter longitudinal cohort study in Jiangsu, China. [PDF]

Alzheimers Dement
Tang L, Chen X, Zhang L, Fan L, Chen N, Li C, Cai Z, Chen G, Chen H, Ye M, Zheng H, Li Q, Ke Z, Hu Z, Cao M, Yang D, Xu S, Xie C, Li X, Xu X, Yu M, Lian X, Hu H, Li H, Cai X, Chen H, Xu W, Cui G, Zhao Y, Dong J, Zhang L, Zhu X, Zhao H, Xu Y.   +33 more
europepmc   +1 more source

Correction: Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data. [PDF]

Alzheimers Res Ther
Noguchi-Shinohara M, Yoshinobu T, Ozaki T, Muramatsu D, Shima A, Sakashita Y, Tada Y, Yamaguchi H, Komatsu J, Ikeda T, Ono K.   +10 more
europepmc   +1 more source